CDKN2A and glioblastoma: Subsequent in vitro studies have shown that CCL13 released from senescence-inducing GBM cells overexpressing p16INK4A can recruit T cells to the tumor tissue, which may help construct a more immunogenic tumor microenvironment, thereby improving the prognosis of GBM patients.38